We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.38B
AUM Growth
+$319M
Cap. Flow
-$48.2M
Cap. Flow %
-0.57%
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$304M
2
ELV icon
Elevance Health
ELV
+$123M
3
XRAY icon
Dentsply Sirona
XRAY
+$102M
4
AGN
Allergan plc
AGN
+$95.1M
5
INSP icon
Inspire Medical Systems
INSP
+$78.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$185M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$154M
3
ABBV icon
AbbVie
ABBV
+$145M
4
THC icon
Tenet Healthcare
THC
+$119M
5
BMY icon
Bristol-Myers Squibb
BMY
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 97.95%
2 Miscellaneous 1.43%
3 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TFX icon
51
Teleflex
TFX
$5.52B
$51.1M 0.61%
190,400
+73,400
+63% +$19.7M
ARGX icon
52
argenx
ARGX
$61.6B
$49.7M 0.59%
599,300
+99,300
+20% +$8.88M
KALA icon
53
KALA BIO
KALA
$11.1M
$47.3M 0.56%
1,381
– –
LKFT
54
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$44.9M 0.54%
486,990
– –
ACET icon
55
Adicet Bio
ACET
$90.8M
$44.2M 0.53%
43,128
– –
EHTH icon
56
eHealth
EHTH
$29.6M
$40.5M 0.48%
1,834,700
– –
ONC
57
BeOne Medicines Ltd
ONC
$39.2B
$40.2M 0.48%
261,400
-93,500
-26% -$16.7M
OBSV
58
DELISTED
ObsEva SA Ordinary Shares
OBSV
$39.4M 0.47%
2,605,531
– –
ZLAB icon
59
Zai Lab
ZLAB
$2.76B
$37.5M 0.45%
1,611,000
+952,840
+145% +$20.5M
MD icon
60
Pediatrix Medical
MD
$2.18B
$37.3M 0.45%
862,600
+492,600
+133% +$23.6M
TNDM icon
61
Tandem Diabetes Care
TNDM
$1.17B
$37.2M 0.44%
+1,689,000
New +$20.8M
CI icon
62
Cigna
CI
$74.2B
$36.5M 0.44%
214,800
+22,500
+12% +$3.89M
EXEL icon
63
Exelixis
EXEL
$13.9B
$36.2M 0.43%
+1,681,200
New +$34.8M
PFE icon
64
Pfizer
PFE
$158B
$35.6M 0.42%
1,035,028
– –
UNH icon
65
UnitedHealth
UNH
$344B
$30.3M 0.36%
+123,300
New +$29.6M
VRTX icon
66
CALL
Vertex Pharmaceuticals
VRTX
$132B
$29.7M 0.35%
+175,000
New +$27.1M
INCY icon
67
Incyte
INCY
$24.8B
$29.3M 0.35%
+438,000
New +$30M
VRCA icon
68
Verrica Pharmaceuticals
VRCA
$84.3M
$29.2M 0.35%
+147,973
New +$29M
CRSP icon
69
CRISPR Therapeutics
CRSP
$5.12B
$29.2M 0.35%
496,200
+391,799
+375% +$22.3M
ASMB icon
70
Assembly Biosciences
ASMB
$590M
$28.3M 0.34%
60,097
– –
IMGN
71
DELISTED
Immunogen Inc
IMGN
$28.3M 0.34%
2,904,270
+1,400,000
+93% +$14.8M
GILD icon
72
Gilead Sciences
GILD
$182B
$25.8M 0.31%
364,600
– –
INSY
73
DELISTED
Insys Therapeutics, Inc.
INSY
$25.4M 0.3%
3,511,544
– –
LPNT
74
DELISTED
LifePoint Health, Inc.
LPNT
$25M 0.3%
513,200
-389,625
-43% -$20.2M
ALPN
75
DELISTED
Alpine Immune Sciences Inc
ALPN
$25M 0.3%
3,298,516
– –
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2018 Portfolio in Review

As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
  • OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
  • OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
  • OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
  • OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
  • OrbiMed opened 20 new positions and closed 14 in Q2 2018.
  • OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.